Who
Sheldon L. Koenig
President and CEO
Company insider
Files Form 4 as: President and CEO, Esperion Therapeutics; EVP, Chief Commercial Officer, Portola Pharmaceuticals.
In numbers
- Trades disclosed
- 57
- Buys
- 2
- Sells
- 13
- Bought
- $75K
- Sold
- $933K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 31 Jan 2019
- Last trade
- 13 Jul 2026
- Last filed
- 13 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Jul 2026filed 13 Jul 2026 | Esperion TherapeuticsBiotechnology | SEC FORM 4 Code D | —2,121,094 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —642,000 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —753,000 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code D | —642,000 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code D | —753,000 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code D | —647,460 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —647,460 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeutics | SEC FORM 4 Code D | —2,121,094 | filing |
| 17 Jun 2026filed 18 Jun 2026 | Esperion TherapeuticsBiotechnology | SEC FORM 4 Sold | $169K53,588 at $3.16 | filing |
| 17 Jun 2026filed 18 Jun 2026 | Esperion Therapeutics | SEC FORM 4 Sold | $169K53,588 at $3.16 | filing |
| 17 Mar 2026filed 18 Mar 2026 | Esperion TherapeuticsBiotechnology | SEC FORM 4 Sold | $70K25,578 at $2.72 | filing |
| 17 Mar 2026filed 18 Mar 2026 | Esperion Therapeutics | SEC FORM 4 Sold | $70K25,578 at $2.72 | filing |
| 13 Mar 2026filed 16 Mar 2026 | Esperion TherapeuticsBiotechnology | SEC FORM 4 Code A | —723,760 at $0.00 | filing |
| 13 Mar 2026filed 16 Mar 2026 | Esperion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —647,460 at $0.00 | filing |
| 13 Mar 2026filed 16 Mar 2026 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code A | —647,460 at $0.00 | filing |
| 13 Mar 2026filed 16 Mar 2026 | Esperion Therapeutics | SEC FORM 4 Code A | —723,760 at $0.00 | filing |
| 17 Dec 2025filed 18 Dec 2025 | Esperion Therapeutics | SEC FORM 4 Sold | $177K48,244 at $3.67 | filing |
| 17 Sep 2025filed 18 Sep 2025 | Esperion Therapeutics | SEC FORM 4 Sold | $79K28,427 at $2.79 | filing |
| 17 Jun 2025filed 18 Jun 2025 | Esperion Therapeutics | SEC FORM 4 Sold | $34K30,474 at $1.11 | filing |
| 18 Mar 2025filed 19 Mar 2025 | Esperion Therapeutics | SEC FORM 4 Sold | $20K13,047 at $1.50 | filing |
News
No headline names them, or the companies they trade most, lately.